Skip to contentN
Northwest Biotherapeutics Inc
N
NWBONorthwest Biotherapeutics Inc Q3 2024 · 10-Q
Revenue$357.00K$357.00K−12.1% vs Q3 2023 Net Income-$19.37M-$19.37MN/M vs Q3 2023 EPS Diluted-$0.02-$0.02N/M vs Q3 2023 Operating Income-$14,801,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Northwest Biotherapeutics Inc · CIK 1072379 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$8,409,000N/M Margins · derivedOperating margin-4145.9%−740.8 pt vs Q3 2023
Net margin-5426.9%−850.5 pt vs Q3 2023
ended Sep 30, 2024 · filed Nov 12, 2024 · 43 d after period end